Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation
Bishoi Aziz(University of Alberta), Andrew L. Mason(Ochsner Medical Center), Emmanuel Tsochatzis(University College London), Aldo J. Montaño‐Loza(University of Alberta), Parthi Srinivasan(King's College - North Carolina), Mansoor Madanur(King's College - North Carolina), Michael Allison(Cambridge University Hospitals NHS Foundation Trust), Keith Roberts(University of Alabama at Birmingham Hospital), Andrea del Monaco(The Royal Free Hospital), Bridget Gunson(NIHR Birmingham Liver Biomedical Research Unit), Giuseppe Fusai(The Royal Free Hospital), G. Sen(Freeman Hospital), Ellina Lytvyak(University of Alberta), Nicola Owen(Cambridge University Hospitals NHS Foundation Trust), Matthew Cheah(University of Alberta), Sophie José(NHS England), Stephen J. Wigmore(Edinburgh Royal Infirmary), Derek Manas, Carlos Moctezuma‐Velázquez(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Anuja Athale(King's College - North Carolina), Felicity Creamer(Edinburgh Royal Infirmary), Vikram Iyer(NIHR Birmingham Liver Biomedical Research Unit), Bimbi Fernando(The Royal Free Hospital), Reena Ravikumar, Beverley Kok(The Royal Free Hospital), Darius Mirza(NIHR Surgical Reconstruction and Microbiology Research Centre), Douglas Thorburn(Royal Free London NHS Foundation Trust), Bettina E. Hansen(Erasmus MC), Shawn Wasilenko(University of Alberta)
Cited by 13
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
|Nature Medicine|2017|1.5k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k